Description
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 4 bp deletion in exon5.,
Disease:Carcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-ETV6, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ETV6 also known as Tel is a transcription factor encoded by the ETV6 gene. It weighs approximately 57 kDa. The protein is expressed in various tissues including hematopoietic cells which are cells that form blood cells. ETV6 contains a pointed (PNT) domain and an ETS DNA-binding domain which allow it to regulate gene expression by binding to specific DNA sequences. It functions in the nucleus where it influences cell cycle progression and differentiation.
Biological function summary
ETV6 impacts processes key to hematopoiesis and is often part of transcriptional regulatory complexes. It guides critical decisions in hematopoietic stem cells promoting lineage commitment and modulating cell cycle regulation. This protein acts as a repressor or activator depending on the context influencing target gene expression and sustaining the balance necessary for blood cell differentiation and maintenance. Its ability to interact with co-factors like HDACs (histone deacetylases) broadens its regulatory potential.
Pathways
ETV6 integrates into signaling pathways that manage cellular development and proliferation. ETV6 participates in the Ras-MAPK pathway which influences cell growth by regulating transcription of genes essential for these processes. It also interacts closely with proteins like ABL1 in this pathway modulating both kinase activity and gene control highlighting the critical connections it maintains in cell signaling networks.
ETV6 exhibits pivotal roles in oncogenic processes such as those observed in leukemia. Its involvement in translocation events like the ETV6-RUNX1 fusion contributes to the pathogenesis of acute lymphoblastic leukemia (ALL) by altering normal gene regulation. Additionally mutations within ETV6 link it to myelodysplastic syndromes with associated proteins in these disorders including FLT3. This connection highlights the pathogenic impact ETV6 permutations can have within hematological malignancies.
